Kamada Ltd Stock Price, News & Analysis

Kamada Ltd. (NASDAQ: KMDA), a commercial stage biopharmaceutical company specializing in rare and serious conditions and plasma-derived products, has scheduled its Q1 2025 financial results announcement for May 14, 2025, before U.S. markets open.

The company will host a conference call for the investment community at 8:30am ET on the same day. Participants can join via phone using specific dial-in numbers for U.S., Israeli, and International callers, or watch the webcast live online.

Kamada (NASDAQ: KMDA) has launched a comprehensive post-marketing research program for CYTOGAM®, its Cytomegalovirus Immune Globulin product. The program includes 10 studies focused on CMV management in solid organ transplantation, conducted with leading U.S. physicians. CYTOGAM® generated $22.5 million in revenue in 2024, a 31% increase from the previous year. Recent studies have shown promising results, including a five-year retrospective study of 325 lung-transplant patients and research showing CYTOGAM has 4-fold higher anti-CMV antibodies than regular IVIGs. The FDA approved Kamada's application to manufacture CYTOGAM in May 2023. The new research program aims to generate data supporting CYTOGAM's benefits in CMV prevention and management, explore new dosing strategies, and investigate potential applications.

Kamada (NASDAQ: KMDA) has provided an update on tax withholding procedures for its previously announced special cash dividend of $0.20 per share (total ~$11.5 million). The dividend will be paid on April 7, 2025, to shareholders of record as of March 17, 2025.

The company has obtained a tax ruling from the Israel Tax Authority that allows Nasdaq shareholders who are residents of countries with Israeli tax treaties to potentially qualify for reduced withholding tax rates. The standard Israeli withholding tax rates are 30% for substantial shareholders and 25% for others.

To benefit from reduced rates, eligible shareholders must submit required documentation to IBI Trust Management (the appointed Tax Agent) by May 5, 2025. The company will initially withhold 25% of the dividend amount, with potential refunds available to qualifying shareholders who complete the necessary paperwork.

Kamada (NASDAQ: KMDA) announced the opening of a new plasma collection center in San Antonio, Texas, marking its third such facility. The 11,100 square foot center, operated by Kamada Plasma, will feature nearly 50 donor beds with an estimated annual collection capacity of 50,000 liters.

The facility will collect both normal source plasma and specialty plasma (Anti-Rabies and Anti-D), supporting the company's increasing demand for hyper-immune plasma while aiming to reduce raw material costs. At full capacity, the center is projected to generate $8-10 million in annual revenue from normal source plasma sales to third parties.

Kamada plans to submit approval applications to the U.S. FDA and European Medicines Agency in the second half of 2025, with anticipated approval decisions expected within 9-12 months of submission.

Kamada (NASDAQ: KMDA) reported strong financial results for 2024, achieving record revenues of $161.0 million, a 13% increase from 2023. The company's adjusted EBITDA reached $34.1 million, up 42% year-over-year, with a 21% margin.

Key financial highlights include net income of $14.5 million ($0.25 per diluted share), up 75% year-over-year, and operating cash flow of $47.6 million. The company ended 2024 with a cash balance of $78.4 million.

Looking ahead, Kamada affirmed its 2025 guidance, projecting revenues of $178-182 million and adjusted EBITDA of $38-42 million. The company also declared a special cash dividend of $0.20 per share, totaling approximately $11.5 million.

Growth drivers include expansion of plasma collection operations, with a third U.S. center opening soon, and advancement of the Inhaled AAT Phase 3 trial, which received FDA approval for reduced patient enrollment to 180 subjects.

Kamada (NASDAQ: KMDA) has declared its first-ever special cash dividend of $0.20 per share (approximately NIS0.72), totaling around $11.5 million. The dividend will be paid on April 7, 2025, to shareholders of record as of March 17, 2025.

The announcement follows Kamada's record revenue and profitability performance in 2024. CEO Amir London emphasized the company's strong financial position and outlined four growth pillars: organic commercial growth, business development and M&A transactions, expansion of plasma collection operations, and advancement of their lead product candidate, Inhaled AAT.

The company will withhold tax on the dividend according to Israeli tax law and is awaiting a ruling from the Israel Tax Authority regarding tax withholding for non-Israeli shareholders.

Kamada (NASDAQ: KMDA; TASE: KMDA.TA), a commercial stage global biopharmaceutical company specializing in rare and serious conditions and specialty plasma-derived products, has scheduled its Fourth Quarter and Fiscal Year 2024 financial results announcement for March 5, 2025, before U.S. markets open.

The company will host an investment community conference call at 8:00 AM ET on the same day. Investors can participate through various dial-in numbers: 1-877-413-7208 (U.S.), 1-201-689-8555 (International), or 1-809-406-247 (Israel) using conference ID 13751522. The call will also be available via webcast.

Kamada (NASDAQ: KMDA) has secured a significant $25 million contract for supplying KAMRAB® and VARIZIG® in Latin America over a three-year period from 2025-2027. This contract with an international organization reinforces Kamada's position in the specialty plasma-derived field.

KAMRAB is used for post-exposure prevention of rabies infection, while VARIZIG is indicated for post-exposure prophylaxis in high-risk individuals for Varicella Zoster. The revenue expected from this contract for 2025 is already included in the company's recently announced revenue guidance.

The agreement demonstrates the global strength of Kamada's specialty immunoglobulin portfolio and supports their multi-year growth outlook. The company plans to pursue additional commercial contracts in key strategic territories beyond the U.S. and Canada.

Kamada (NASDAQ: KMDA) has affirmed its 2024 financial guidance and provided strong growth projections for 2025. The company expects to achieve its 2024 targets of $158-162 million in revenue and $32-35 million in adjusted EBITDA, with year-end cash of $78 million.

For 2025, Kamada forecasts continued double-digit growth with revenue of $178-182 million and adjusted EBITDA of $38-42 million, representing year-over-year increases of 13% and 19% respectively at the mid-point of guidance.

Key strategic initiatives include:

• Pursuing new business development and M&A opportunities
• Expanding plasma collection operations with a third center in San Antonio, TX by Q1 2025
• Reducing the sample size of their Inhaled AAT clinical trial from 220 to 180 patients, with an interim futility analysis planned by end of 2025